Skip to main content

Table 2 Treatment regimen for patients with CRE infection

From: Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia

Variable

n (%)

Any carbapenem (meropenem, imipenem, ertapenem)

131 (69.3)

Aminoglycoside (amikacin, gentamicin)

38 (20.1)

Aztreonam

11 (5.8)

CAZ-AVI

89 (47.1)

Colistin

78 (41.3)

Tigecycline

62 (32.8)

  1. CAZ-AVI ceftazidime-avibactam